Literature DB >> 23787723

Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups.

Petar M Seferovic1, Stefan Stoerk, Gerasimos Filippatos, Viacheslav Mareev, Ausra Kavoliuniene, Arsen D Ristic, Piotr Ponikowski, John McMurray, Aldo Maggioni, Frank Ruschitzka, Dirk J van Veldhuisen, Andrew Coats, Massimo Piepoli, Theresa McDonagh, Jillian Riley, Arno Hoes, Burkert Pieske, Milan Dobric, Zoltan Papp, Alexandre Mebazaa, John Parissis, Tuvia Ben Gal, Dragos Vinereanu, Dulce Brito, Johann Altenberger, Plamen Gatzov, Ivan Milinkovic, Jaromír Hradec, Jean-Noel Trochu, Offer Amir, Brenda Moura, Mitja Lainscak, Josep Comin, Gerhard Wikström, Stefan Anker.   

Abstract

AIMS: The aim of this document was to obtain a real-life contemporary analysis of the demographics and heart failure (HF) statistics, as well as the organization and major activities of the Heart Failure National Societies (HFNS) in European Society of Cardiology (ESC) member countries. METHODS AND
RESULTS: Data from 33 countries were collected from HFNS presidents/representatives during the first Heart Failure Association HFNS Summit (Belgrade, Serbia, 29 October 2011). Data on incidence and/or prevalence of HF were available for 22 countries, and the prevalence of HF ranged between 1% and 3%. In five European and one non-European ESC country, heart transplantation was reported as not available. Natriuretic peptides and echocardiography are routinely applied in the management of acute HF in the median of 80% and 90% of centres, respectively. Eastern European and Mediterranean countries have lower availability of natriuretic peptide testing for acute HF patients, compared with other European countries. Almost all countries have organizations dealing specifically with HF. HFNS societies for HF patients exist in only 12, while in 16 countries HF patient education programmes are active. Most HFNS reported that no national HF registry exists in their country. Fifteen HFNS produced national HF guidelines, while 19 have translated the ESC HF guidelines. Most HFNS (n = 23) participated in the organization of the European HF Awareness Day.
CONCLUSION: This document demonstrated significant heterogeneity in the organization of HF management, and activities of the national HF working groups/associations. High availability of natriuretic peptide and echocardiographic measurements was revealed, with differences between developed countries and countries in transition.

Entities:  

Keywords:  Heart Failure Association; National societies; Organization of heart failure management

Mesh:

Year:  2013        PMID: 23787723     DOI: 10.1093/eurjhf/hft092

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  29 in total

1.  How does a clinical trial fit into the real world? The RELAX-AHF study population into the EAHFE registry.

Authors:  Òscar Miró; Víctor Gil; Christian Müller; Alexander Mebazaa; Héctor Bueno; Francisco Javier Martín-Sánchez; Pablo Herrero; Javier Jacob; Pere Llorens
Journal:  Clin Res Cardiol       Date:  2015-04-24       Impact factor: 5.460

2.  Health awareness days: sufficient evidence to support the craze?

Authors:  Jonathan Purtle; Leah A Roman
Journal:  Am J Public Health       Date:  2015-04-16       Impact factor: 9.308

Review 3.  Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps.

Authors:  Robert J Mentz; Lothar Roessig; Barry H Greenberg; Naoki Sato; Kaori Shinagawa; Daniel Yeo; Bernard W K Kwok; Eugenio B Reyes; Henry Krum; Burkert Pieske; Stephen J Greene; Andrew P Ambrosy; Jacob P Kelly; Faiez Zannad; Bertram Pitt; Carolyn S P Lam
Journal:  JACC Heart Fail       Date:  2016-06       Impact factor: 12.035

4.  Prognostic value of selected echocardiographic, impedance cardiographic, and hemodynamic parameters determined during right heart catheterization in patients qualified for heart transplantation.

Authors:  Wojciech Gilewski; Jarosław Pietrzak; Joanna Banach; Robert Bujak; Jan Błażejewski; Danuta Karasek; Łukasz Wołowiec; Władysław Sinkiewicz
Journal:  Heart Vessels       Date:  2017-09-22       Impact factor: 2.037

5.  The Key Roles for the Nurse in Acute Heart Failure Management.

Authors:  Jillian Riley
Journal:  Card Fail Rev       Date:  2015-10

6.  Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial.

Authors:  Mira-Lynn Chavanon; Simone Inkrot; Christine Zelenak; Elvis Tahirovic; Dragana Stanojevic; Svetlana Apostolovic; Aleksandra Sljivic; Arsen D Ristic; Dragan Matic; Goran Loncar; Jovan Veskovic; Marija Zdravkovic; Mitja Lainscak; Burkert Pieske; Christoph Herrmann-Lingen; Hans-Dirk Düngen
Journal:  Clin Res Cardiol       Date:  2017-03-30       Impact factor: 5.460

Review 7.  An integrated review of interventions to improve psychological outcomes in caregivers of patients with heart failure.

Authors:  Lorraine S Evangelista; Anna Strömberg; J Nicholas Dionne-Odom
Journal:  Curr Opin Support Palliat Care       Date:  2016-03       Impact factor: 2.302

8.  Lycopene dietary intervention: a pilot study in patients with heart failure.

Authors:  Martha J Biddle; Terry A Lennie; Gregory V Bricker; Rachel E Kopec; Steven J Schwartz; Debra K Moser
Journal:  J Cardiovasc Nurs       Date:  2015 May-Jun       Impact factor: 2.083

Review 9.  Left ventricular assist devices: a kidney's perspective.

Authors:  T R Tromp; N de Jonge; J A Joles
Journal:  Heart Fail Rev       Date:  2015-07       Impact factor: 4.214

10.  MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure.

Authors:  Chris J Watson; Shashi K Gupta; Eoin O'Connell; Sabrina Thum; Nadezhda Glezeva; Jasmin Fendrich; Joe Gallagher; Mark Ledwidge; Lea Grote-Levi; Kenneth McDonald; Thomas Thum
Journal:  Eur J Heart Fail       Date:  2015-03-04       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.